Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Histone deacetylase inhibitors: overview and perspectives Dokmanovic M; Clarke C; Marks PAMol Cancer Res 2007[Oct]; 5 (10): 981-9Histone deacetylase inhibitors (HDACi) comprise structurally diverse compounds that are a group of targeted anticancer agents. The first of these new HDACi, vorinostat (suberoylanilide hydroxamic acid), has received Food and Drug Administration approval for treating patients with cutaneous T-cell lymphoma. This review focuses on the activities of the 11 zinc-containing HDACs, their histone and nonhistone protein substrates, and the different pathways by which HDACi induce transformed cell death. A hypothesis is presented to explain the relative resistance of normal cells to HDACi-induced cell death.|*Histone Deacetylase Inhibitors[MESH]|Antineoplastic Agents/*chemistry/*pharmacology/therapeutic use[MESH]|Clinical Trials as Topic[MESH]|Enzyme Inhibitors/*chemistry/*pharmacology/therapeutic use[MESH]|Histone Deacetylases/classification/metabolism[MESH]|Humans[MESH]|Metalloproteins/*antagonists & inhibitors/classification/metabolism[MESH]|Neoplasms/drug therapy/*enzymology[MESH]|Zinc/metabolism[MESH] |